We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting epidermal growth factor receptor--are we missing the mark?
- Authors
Dancey, Janet E; Freidlin, Boris
- Abstract
Aberrant signalling through the epidermal growth factor receptor (EGFR) is associated with neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis. The high frequency of abnormalities in EGFR signalling in human carcinomas and gliomas and laboratory studies showing that inhibition of EGFRcan impair tumour growth means that EGFR is an attractive target for the development of cancer therapeutics. Among the classes of agents targeting EGFR in clinical development are monoclonal antibodies against the extracellular ligand-binding domain of the receptor, and small molecules that inhibit activation of the receptor tyrosine kinase. Although there are pharmacological and mechanistic differences between the two classes of inhibitor, preclinical studies suggest they both inhibit cell proliferation and have additive or synergistic cytotoxicity with standard therapies. Results from early clinical trials indicate that these agents are well tolerated and have anti-tumour activity.
- Publication
Lancet (London, England), 2003, Vol 362, Issue 9377, p62
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(03)13810-X